Genworth (GNW) Q4 2025 earnings review
Enact Prints Cash, Legacy LTC Burns It
Genworth's Q4 2025 results vividly illustrate its dual nature. The Enact mortgage insurance segment remains a cash-generating engine, delivering $146M in adjusted operating income and driving 8% YoY growth in New Insurance Written. However, the Closed Block is hemorrhaging. Long-Term Care (LTC) operating losses collapsed to $159M due to severe claim pressures and unfavorable assumption updates. As a result, consolidated Net Income flatlined at $2M. While Enact's distributions fund aggressive share buybacks, the structural deterioration in the legacy LTC block prevents meaningful bottom-line value creation.
🐂 Bull Case
Enact's PMIERs sufficiency ratio sits at a fortress-like 162% ($1.9B above requirements). The segment just authorized a massive new $500M share repurchase program, ensuring a steady stream of capital returns to Genworth.
The CareScout Quality Network now covers 95% of the US 65+ population, delivering 925 provider matches in Q4. The recent $15M acquisition of Seniorly accelerates Genworth's direct-to-consumer reach.
🐻 Bear Case
The legacy LTC block is unraveling faster than expected. Q4 saw $124M in unfavorable actual-to-expected variances due to higher claims and lower terminations, cementing a baseline of structural unprofitability.
Net investment income was dragged down by a $31M net investment loss in Q4, driven by volatile mark-to-market adjustments on limited partnerships and trading losses.
⚖️ Verdict: ⚪
Neutral. Enact provides a formidable cash floor and funds aggressive share repurchases, but the accelerating deterioration in the legacy LTC block severely caps Genworth's upside potential.
Key Themes
Enact Delivers Accelerated Growth
Accelerating. Enact remains Genworth's primary value driver. Primary New Insurance Written (NIW) grew 8% YoY to $14.4B in Q4, driving primary insurance in-force up 2% to $273.1B. Adjusted operating income hit $146M, aided by a $60M pre-tax reserve release reflecting favorable cure performance. This cash cow is completely underwriting the parent company's capital allocation strategy.
LTC Experience Variances Widen Dramatically
Decelerating/Reversing. The narrative that in-force rate actions (IFAs) will stabilize the LTC block is failing. Q4 posted a staggering $124M in unfavorable actual-to-expected (A/E) experience due to higher claims and lower terminations, a sharp acceleration from $97M a year ago. Favorable COVID-era mortality has completely dissipated, exposing the brutal reality of an aging policyholder block.
Macro Bite: Cost of Care Inflation
Macro cost of care inflation is directly eroding the LTC balance sheet. Management was forced to take a $47M unfavorable pre-tax assumption update in Q4, explicitly citing near-term benefit utilization and healthy life mortality updates. While the MYRAP has generated $34.5B in estimated NPV since 2012, inflation is clearly outpacing the company's ability to secure premium hikes.
CareScout Innovation: Care Assurance & Seniorly
Genworth is heavily pivoting toward its CareScout ecosystem. The company launched 'Care Assurance'—its inaugural stand-alone LTC insurance product—which is now live in 39 states. Furthermore, the $15M cash acquisition of Seniorly accelerates CareScout's direct-to-consumer footprint, adding placement fee revenue to the network's economics. This is Genworth's primary offensive move.
Corporate Drag from Growth Investments
The CareScout transformation comes at a steep near-term price. The Corporate and Other segment reported an adjusted operating loss of $24M in Q4 (up from $21M in Q3 and $23M in 24Q4), specifically driven by continued investments in the CareScout platform and debt service. This contradicts the rosy narrative around the new segment's long-term potential, as it is actively burning cash today.
Aggressive Capital Returns
Stable. Management executed $94M in share repurchases in Q4 at an average price of $8.66 per share, bringing the 2025 total to $245M. Since the program's inception, Genworth has retired $790M in stock at an average of $6.21. Holding company cash remains adequate at $234M to sustain this pace, entirely bankrolled by Enact dividends.
Other KPIs
Decelerating. Down from $631M sequentially and $626M in the prior year. The decline was primarily driven by lower income from limited partnerships. Furthermore, net investment losses swung to a $31M drag in the quarter, pressured by mark-to-market adjustments.
Stable. The GLIC consolidated Risk-Based Capital (RBC) ratio ended at an estimated 300%, down slightly from 306% a year ago. This reflects higher required capital as the limited partnership portfolio grows, offset by $71M in statutory pre-tax earnings for the year.
Guidance
In February 2026, Enact announced a new share repurchase authorization up to $500M. This signals accelerating capital return capacity from the subsidiary, which serves as the sole lifeline for Genworth's holding company cash flow and parent-level buybacks.
Key Questions
LTC Baseline Deterioration
With LTC actual-to-expected variance hitting a severe $124M unfavorable mark this quarter, has the baseline for the quarterly operating drag structurally stepped down, or were there anomalous seasonal factors driving the severity?
CareScout Breakeven Timeline
You acquired Seniorly for $15M and continue to incur Corporate segment losses to build out CareScout. What is the updated timeline for CareScout Services and Care Assurance to reach cash flow breakeven and offset these holding company expenses?
PMIERs vs Parent Capital Allocation
With Enact authorizing a massive $500M buyback, how does Genworth plan to balance participating in Enact's buybacks versus directing those cash flows strictly into Genworth-level repurchases or debt retirement?